Outset Medical, Inc. 8-K

What Happened

• Outset Medical, Inc. filed an 8-K on January 12, 2026 announcing a press release with preliminary, unaudited expected revenue for the fourth quarter and full year ended December 31, 2025. The company notes this financial information is subject to change during quarter‑ and year‑end close and will be finalized in its Form 10‑K.
• The company also disclosed a Board change: director Andrea Saia stepped down (resignation effective January 9, 2026) and the Board appointed Karen Prange effective January 9, 2026. An updated investor presentation was posted on the company website. The filing was signed by CFO Renee Gaeta.

Key Details

• Press release and investor presentation furnished as Exhibits 99.1 and 99.2 (filed with the 8‑K on Jan 12, 2026).
• Financial results described as preliminary and unaudited; final audited results will appear in the Company’s Annual Report on Form 10‑K for the year ended Dec 31, 2025.
• Director change timeline: Andrea Saia resigned (effective Jan 9, 2026); Karen Prange appointed Jan 8, 2026 (effective Jan 9, 2026) to fill the Class III director seat through the 2026 annual meeting.
• Director compensation for Ms. Prange per amended policy (effective Jan 8, 2026): initial grant of 18,667 RSUs vesting quarterly over three years; annual grant of 10,667 RSUs vesting upon the earlier of one year after grant or the next annual meeting. Ms. Prange was named a member of the Compensation Committee and is designated an independent director.

Why It Matters

• The preliminary revenue disclosure gives investors an early view of Outset’s near‑term top‑line performance, but figures are unaudited and may change when the company completes its year‑end close and files the Form 10‑K.
• The board change replaces one director with an experienced medical‑device executive (Karen Prange), which may affect board composition and expertise; her equity awards will result in future RSU vesting per the disclosed schedule.
• The company’s updated investor presentation and the forward‑looking statement caution remind investors that expectations are subject to risks and that final audited results are pending.